Komori
Financial Results Presentation3583AuBEX CORPORATIONMaterials and Chemicals

Supplementary Explanatory Materials for the Second Quarter of the Fiscal Year Ending March 2027

For the cumulative second quarter of the fiscal year ending March 2027, consolidated net sales, operating income and interim net income fell below the same period of the previous year due to a substantial decline in sales in the Techno Products business and higher manufacturing costs. Meanwhile, the Medical Products business posted higher sales and earnings.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
9.3
Year-on-year decline in consolidated net sales (%)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial Results PresentationFiscal year ending March 2027, second quarter (first half)10 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales2,772 Millions of yen-9.3%
Operating profit269 Millions of yen-23.4%
Ordinary income250 Millions of yen-28.5%
Net income126 Millions of yen-64.3%
Operating profit margin9.7 %
Results for the three months of the current quarter
Net Sales
1,338 Millions of yen
Operating profit
77 Millions of yen
Full-year earnings forecast
Net Sales
6,000 Millions of yen
Operating profit
500 Millions of yen
Ordinary income
480 Millions of yen
Profit attributable to owners of the parent
330 Millions of yen
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales46.2
Operating profit53.8
Ordinary income52.2
Profit attributable to owners of the parent38.4
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
Decrease from the same period last year
284 Millions of yen
Factors
  • Decline in sales in the Techno Products business
  • Weak sales of pen tips for writing instruments in the Chinese market
  • Firm sales of drug solution injectors in the Medical Products business
Operating profit
Decrease from the same period last year
82 Millions of yen
Factors
  • Decline in sales in the Techno Products business
  • Rising Energy Prices
  • Higher raw-material prices
  • Rising manufacturing costs
New initiatives
  • Strengthen the development of high-value-added Techno Products
  • Accelerate the full-scale overseas expansion of Medical Products
  • Renovate existing plants and build new plants to increase production
  • Create a third business by bringing together the group's core technologies
  • Develop and expand sales of environmentally friendly products
  • Improve employee engagement through investment in human capital
Key KPIsA metric the company considers important as a management benchmark.
  • Techno Products business net sales1,893 Millions of yen-15.0%
  • Medical Products business net sales878 Millions of yen+6.1%
  • Techno Products business segment income342 Millions of yen-23.6%
  • Medical Products business segment income80 Millions of yen+38.5%
  • Net sales by region: Japan1,185 Millions of yen+5.3%
  • Net sales by region: Asia1,033 Millions of yen-30.0%
  • Net sales by region: Europe369 Millions of yen+41.7%
  • Net sales by region: North America123 Millions of yen+10.9%
  • Net sales by region: Latin America24 Millions of yen-49.1%
Segment results
Techno Products Business
Net Sales
1,893 Millions of yen-15.0%
Segment profit
342 Millions of yen-23.6%
Medical Products Business
Net Sales
878 Millions of yen+6.1%
Segment profit
80 Millions of yen+38.5%
Medium-term management plan targets
Final yearFY2027 / 143rd term
Net Sales
¥70 100 million
Operating profit
¥10 100 million
Operating profit margin
14.3 %
ROE
9 % or higher
3-year cumulative capital expenditure under the medium-term plan
¥15 100 million or more
Comparison with actual resultsThe 140th-term results were net sales of ¥6.03 billion, operating income of ¥840 million and ROE of 8.9%.
Financial targets
ROE
Target9% or more
Actual results8.9% in the 140th term
Number of employees
353 People consolidated, as of 31 March 2026
Capital expenditures
¥15 X billion or more three-year cumulative target under the medium-term plan
Annual Dividend
¥35 per share
Payout ratio
28.9 %
Contents of this document
ItemDetails
Document typeFinancial Results Presentation
Fiscal Period CoveredFiscal year ending March 2027, second quarter (first half)
Net Sales2,772 Millions of yen (YoY -9.3%)
Operating profit269 Millions of yen (YoY -23.4%)
Ordinary income250 Millions of yen (YoY -28.5%)
Net income126 Millions of yen (YoY -64.3%)
Operating profit margin9.7 %
Results for the three months of the current quarterNet Sales 1,338 Millions of yen / Operating profit 77 Millions of yen
Full-year earnings forecastNet Sales 6,000 Millions of yen / Operating profit 500 Millions of yen / Ordinary income 480 Millions of yen / Profit attributable to owners of the parent 330 Millions of yen
Progress against full-year forecastNet Sales 46.2 / Operating profit 53.8 / Ordinary income 52.2 / Profit attributable to owners of the parent 38.4
Segment resultsTechno Products Business Net Sales 1,893 Millions of yen (YoY -15.0%) / Segment profit 342 Millions of yen (YoY -23.6%) / Medical Products Business Net Sales 878 Millions of yen (YoY +6.1%) / Segment profit 80 Millions of yen (YoY +38.5%)
Breakdown of Factors Affecting the ChangeNet Sales Decrease from the same period last year 284 Millions of yen / Factors Decline in sales in the Techno Products business, Weak sales of pen tips for writing instruments in the Chinese market, Firm sales of drug solution injectors in the Medical Products business / Operating profit Decrease from the same period last year 82 Millions of yen / Factors Decline in sales in the Techno Products business, Rising Energy Prices, Higher raw-material prices, Rising manufacturing costs
Key KPIs1,893 Millions of yen (YoY -15.0%), 878 Millions of yen (YoY +6.1%), 342 Millions of yen (YoY -23.6%), 80 Millions of yen (YoY +38.5%), 1,185 Millions of yen (YoY +5.3%), 1,033 Millions of yen (YoY -30.0%), 369 Millions of yen (YoY +41.7%), 123 Millions of yen (YoY +10.9%), 24 Millions of yen (YoY -49.1%)
Number of employees353 People (consolidated, as of 31 March 2026)
Medium-term management plan targetsFinal year FY2027 / 143rd term / Net Sales ¥70 100 million / Operating profit ¥10 100 million / Operating profit margin 14.3 % / ROE 9 % or higher / 3-year cumulative capital expenditure under the medium-term plan ¥15 100 million or more / Comparison with actual results The 140th-term results were net sales of ¥6.03 billion, operating income of ¥840 million and ROE of 8.9%.
Financial targetsROE Target 9% or more / Actual results 8.9% in the 140th term
Annual Dividend¥35 per share
Payout ratio28.9 %
Capital expenditures¥15 X billion or more (three-year cumulative target under the medium-term plan)
New initiativesStrengthen the development of high-value-added Techno Products, Accelerate the full-scale overseas expansion of Medical Products, Renovate existing plants and build new plants to increase production, Create a third business by bringing together the group's core technologies, Develop and expand sales of environmentally friendly products, Improve employee engagement through investment in human capital
Items this document does not state (11)
Gross Profit MarginSelling, general and administrative expensesSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In the Techno Products business, sales of pen tips for writing instruments remained sluggish in the Chinese market. Operating income was affected not only by lower sales but also by higher manufacturing costs, including raw materials, energy and logistics costs. Interim net income declined due to lower operating income, the recognition of extraordinary losses and higher tax expenses. Meanwhile, in the Medical Products business, sales of drug solution injectors and guidewires remained firm as a result of active promotional activities.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Explanatory Materials for the Second Quarter of the Fiscal Year Ending March 2027 | AuBEX CORPORATION (3583) timely disclosure | Komori